San Francisco incubator QB3 is linking up with pharma giant GlaxoSmithKline ($GSK) on some translational work, looking to push a few academic research projects toward the clinic. QB3@953 will work with the folks at GSK to find some promising collaborations to work on. This is the latest in a long lineup of discovery deals for GlaxoSmithKline, which set up its Discovery Partnerships with Academia (DPAc) team to find promising new programs. GSK may be busy in the early-stage field, but it's been losing the interest of Wall Street analysts who are distinctly not excited by its weak set of late-stage prospects. Release